Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial

Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial

Background: In metastatic breast cancer (MBC) patients, no biomarker predicting benefit to a bevacizumab-containing therapy has been established yet. MicroRNAs (miRNAs) are involved in angiogenesis and treatment resistance and therefore could be of predictive value. Methods: Profiling of 754 miRNAs...

Full description

Bibliographic Details
Main Authors: Gabriel Rinnerthaler, Simon Peter Gampenrieder, Hubert Hackl, Markus Steiner, Claudia Monzo-Fuentes, Thomas Melchardt, Teresa Magnes, Florian Huemer, Theresa Westphal, Clemens Hufnagl, Cornelia Hauser-Kronberger, Alexander Egle, Richard Greil
Format: Article
Language:English
Published: MDPI AG 2020-06-01
Series:Journal of Clinical Medicine
Subjects:
breast cancer
microRNA
miR-20a-5p
bevacizumab
predictive biomarker
Online Access:https://www.mdpi.com/2077-0383/9/6/1663

Internet

https://www.mdpi.com/2077-0383/9/6/1663

Similar Items